PNU-96415E | CAS# 170856-41-4 | Antipsychotic agent

MedKoo Cat#: 574848 | Name: PNU-96415E

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PNU-96415E is an antipsychotic agent that displays high affinity for dopamine D4 and serotonergic 5-HT2A receptors. It inhibits exploratory locomotor activity and antagonizes d-amphetamine-induced locomotor stimulation in rats.

Chemical Structure

PNU-96415E

CAS# 170856-41-4

Theoretical Analysis

MedKoo Cat#: 574848

Name: PNU-96415E

CAS#: 170856-41-4

Chemical Formula: C21H27Cl2FN2O

Exact Mass: 412.1484

Molecular Weight: 413.36

Elemental Analysis: C, 61.02; H, 6.58; Cl, 17.15; F, 4.60; N, 6.78; O, 3.87

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 500.00	2 Weeks
50mg	USD 1,215.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

PNU-96415E; PNU 96415E; PNU96415E

IUPAC/Chemical Name

1-[2-(3,4-Dihydro-1H-2-benzopyran-1-yl)ethyl]-4-(4-fluorophenyl)piperazine dihydrochloride

InChi Key

OGMGYKPECFQXJJ-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H25FN2O.2ClH/c22-18-5-7-19(8-6-18)24-14-12-23(13-15-24)11-9-21-20-4-2-1-3-17(20)10-16-25-21;;/h1-8,21H,9-16H2;2*1H

SMILES Code

FC1=CC=C(N2CCN(CCC3C4=CC=CC=C4CCO3)CC2)C=C1.[H]Cl.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

PNU-96415E is a selective D4/5-HT2A antagonist.

In vitro activity:

TBD

In vivo activity:

PNU-96415E inhibited exploratory locomotor activity in mice and rats, and antagonized d-amphetamine-induced locomotor stimulation in rats. It antagonized apomorphine-induced cage climbing, and blocked head and body twitch produced by 5-HTP in mice. Like clozapine, but unlike haloperidol, PNU-96415E did not antagonize stereotypic behaviors produced by a high dose of d-amphetamine or methylphenidate in rats and mice. PNU-96415E blocked conditioned avoidance in rats but produced no catalepsy, a pattern similar to clozapine but different from haloperidol. Reference: J Pharmacol Exp Ther. 1997 Apr;281(1):440-7. https://pubmed.ncbi.nlm.nih.gov/9103528/

Preparing Stock Solutions

The following data is based on the product molecular weight 413.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

Tang AH, Franklin SR, Himes CS, Smith MW, Tenbrink RE. PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties. J Pharmacol Exp Ther. 1997 Apr;281(1):440-7. PMID: 9103528.

In vitro protocol:

TBD

In vivo protocol:

1. Tang et al (1997) PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties. J.Pharmacol.Exp.Ther. 281 440 PMID: 9103528 2. Goudie et al (1998) Discriminative stimulus properties of the atypical neuroleptic cloz. in rats: tests with subtype selective receptor ligands. Behav.Pharmacol. 9 699 PMID: 9890260 3: Dolma, S. (2016). Investigation of Neurochemicals' Role in Glioblastoma and Neural Stem Cells: Characterization of Dopamine Receptor D4 Inhibition in Glioblastoma Stem Cells. University of Toronto (Canada). 4: Grant, C. E., Flis, A. L., & Ryan, B. M. (2022). Understanding the role of dopamine in cancer: past, present and future. Carcinogenesis, 43(6), 517-527.